Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting.
Kumarasamy N, Venkatesh KK, Devaleenol B, Saghayam S, Manohar D, Poongulali S, Yepthomi T, Ambrose P, Solomon S, Mayer KH. Kumarasamy N, et al. Among authors: yepthomi t. Int J Infect Dis. 2009 Nov;13(6):e360-4. doi: 10.1016/j.ijid.2008.11.030. Epub 2009 Mar 27. Int J Infect Dis. 2009. PMID: 19328734 Free article.
Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients.
Kumarasamy N, Venkatesh KK, Devaleenal B, Poongulali S, Yepthomi T, Solomon S, Flanigan TP, Mayer KH. Kumarasamy N, et al. Among authors: yepthomi t. J Int Assoc Physicians AIDS Care (Chic). 2011 Mar-Apr;10(2):71-5. doi: 10.1177/1545109710382780. Epub 2011 Jan 24. J Int Assoc Physicians AIDS Care (Chic). 2011. PMID: 21266320 Free PMC article.
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings.
Kumarasamy N, Madhavan V, Venkatesh KK, Saravanan S, Kantor R, Balakrishnan P, Devaleenal B, Poongulali S, Yepthomi T, Solomon S, Mayer KH, Benson C, Schooley R. Kumarasamy N, et al. Among authors: yepthomi t. Clin Infect Dis. 2009 Jul 15;49(2):306-9. doi: 10.1086/600044. Clin Infect Dis. 2009. PMID: 19522657 Free PMC article.
The association between HIV-1 subtype C antiretroviral resistance and HLA prevalence in southern India.
Saravanan S, Madhavan V, Murugavel KG, Balakrishnan P, Solomon SS, Umapathy S, Kantor R, Kumarasamy N, Yepthomi T, Smith DM, Mayer KH, Solomon S. Saravanan S, et al. Among authors: yepthomi t. J Acquir Immune Defic Syndr. 2011 May 1;57(1):e17-9. doi: 10.1097/QAI.0b013e3182169050. J Acquir Immune Defic Syndr. 2011. PMID: 21775932 Free PMC article. No abstract available.
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
Kumarasamy N, Venkatesh KK, Devaleenal B, Palanivel V, Cecelia AJ, Muthu S, Yepthomi T, Mayer KH, Flanigan T. Kumarasamy N, et al. Among authors: yepthomi t. J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):598-600. doi: 10.1097/QAI.0b013e318074ef99. J Acquir Immune Defic Syndr. 2007. PMID: 17704685 Clinical Trial. No abstract available.
22 results